Related Experiment Video
Updated: Jun 4, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients
Jian Zhu1, Jianling Zuo, Qinian Xu
1Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, PR China.
Abstract:
Gliomas are the most common human brain tumours and can be classified into four grades based on clinical and pathological criteria. A recent cancer genome-sequencing project revealed that more than 70% of low-grade gliomas bear mutations in one of two NAD(+)-dependent isocitrate dehydrogenase enzymes, namely, IDH1 and IDH2. Based on the findings that glioma-derived mutations in IDH1 can inhibit the catalytic activity of the enzyme, induce HIF-1α, and can produce 2-hydroxyglutarate, two research groups speculated that the IDH mutations may contribute to the promotion of tumorigenesis in gliomas. However, they cannot fully explain the phenomenon that patients harbouring such mutations usually have better outcomes than those with the wild-type IDH genes. This fact leads us to hypothesize that the IDH mutations are not the origin of gliomas but a subsequent protective mechanism that interferes with the metabolism of the tumour cells, making these cells fragile and susceptible to cell death. This process finally helps patients who harbour such IDH mutations to survive. Therefore, contrary to the proposals of other researchers, we speculate that any interventions that correct the impaired function of the mutant IDHs, such as the use of cell-permeable α-ketoglutarate derivatives, may not cure gliomas and may even worsen the disease.
Insights
Mutations in isocitrate dehydrogenase (IDH) enzymes in gliomas may not cause cancer but act as a protective mechanism. Interventions correcting these IDH mutations might worsen the disease, contrary to current therapeutic hypotheses.
Area of Science:
- Neuro-oncology
- Cancer Genomics
- Metabolic Pathways
Background:
- Gliomas are common brain tumors graded by clinical and pathological criteria.
- Over 70% of low-grade gliomas have mutations in NAD(+)-dependent isocitrate dehydrogenase (IDH) enzymes (IDH1 and IDH2).
- Previous research linked IDH1 mutations to inhibited enzyme activity, HIF-1α induction, and 2-hydroxyglutarate production, suggesting a role in tumorigenesis.
Purpose of the Study:
- To investigate the role of IDH mutations in glioma development and patient outcomes.
- To propose an alternative hypothesis for the observed better prognosis in patients with IDH mutations.
- To re-evaluate the potential therapeutic strategies targeting IDH mutations.
Main Methods:
- Review and analysis of existing cancer genome-sequencing data.
- Hypothesis generation based on conflicting findings regarding IDH mutations and patient survival.
- Comparative analysis of proposed mechanisms of IDH mutation effects in gliomas.
Main Results:
- IDH mutations are associated with better patient outcomes, contradicting theories of direct tumorigenesis.
- The protective effect of IDH mutations is hypothesized to stem from increased tumor cell fragility and susceptibility to cell death.
- The study challenges the notion that IDH mutations are the primary drivers of glioma.
Conclusions:
- IDH mutations in gliomas may represent a protective cellular response rather than an initiating oncogenic event.
- Interventions aimed at correcting mutant IDH function could potentially be detrimental to patients.
- Further research is needed to understand the complex role of IDH mutations in glioma biology and to guide therapeutic development.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...